论文部分内容阅读
目的:分析左氧氟沙星对幽门螺杆菌阳性的慢性萎缩性胃炎患者的临床疗效和安全性。方法:选取2013年10月—2015年10月间收治的幽门螺杆菌阳性的慢性萎缩性胃炎患者82例,将其分为对照组和治疗组,每组41例;对照组患者均给予阿莫西林、奥美拉唑、甲硝唑3种药物联合治疗;治疗组患者均给予左氧氟沙星、奥美拉唑、甲硝唑3种药物联合治疗,比较两组患乾治疗后的总有效率、幽门螺杆菌清除率。结果:治疗组患者治疗后对社区幽门螺杆菌阳性的慢性萎缩性胃炎患者总有效率明显优于对照组(P<0.05);幽门螺杆菌检测结果转阴时间、胃炎症状消失时间、药物治疗总时间明显短于对照组(P<0.05);药物不良反应的发生率明显少于对照组(P<0.05)。结论:采用左氧氟沙星组合药物治疗幽门螺杆菌阳性的慢性萎缩性胃炎患者的疗效优于阿莫西林组合药物治疗。
Objective: To analyze the clinical efficacy and safety of levofloxacin against helicobacter pylori-positive chronic atrophic gastritis. Methods: A total of 82 patients with Helicobacter pylori-positive chronic atrophic gastritis were selected from October 2013 to October 2015. They were divided into control group and treatment group, 41 cases in each group. Patients in control group were given Amo Xilin, omeprazole, metronidazole three kinds of drugs combined treatment; patients were treated with levofloxacin, omeprazole, metronidazole three kinds of drugs combined treatment, the two groups compared the total effective rate after treatment, pylorus Helicobacter clearance. Results: After treatment, the total effective rate of H.pylori-positive patients with chronic atrophic gastritis in the treatment group was significantly better than that in the control group (P <0.05). The H. pylori test results showed that the test results turned negative, the disappearance of gastritis symptom, The time was significantly shorter than the control group (P <0.05); the incidence of adverse drug reactions was significantly less than the control group (P <0.05). Conclusion: The levofloxacin combination therapy in patients with Helicobacter pylori-positive chronic atrophic gastritis is superior to amoxicillin combination therapy.